Research programme: antisense oligonucleotides - Lorus Therapeutics

Drug Profile

Research programme: antisense oligonucleotides - Lorus Therapeutics

Alternative Names: GTI-2601; GTI-3008; GTI-3601; GTI-3602; GTI-3603; GTI-3604; GTI-3610; GTI-3611; GTI-3612; GTI-4006; LOR-1284; siRNA-1284

Latest Information Update: 24 Nov 2011

Price : $50

At a glance

  • Originator Lorus Therapeutics
  • Class Antisense oligonucleotides; Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Cancer; Renal cancer

Most Recent Events

  • 24 Nov 2011 Research programme: antisense oligonucleotides - Lorus Therapeutics is available for licensing as of 11 Nov 2011. http://www.lorusthera.com
  • 14 Nov 2011 Discontinued - Preclinical for Cancer in Canada (IV)
  • 14 Nov 2011 Discontinued - Preclinical for Renal cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top